Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

H Buller, M Prins, A Lensing, H Decousus, Barry Jacobson, E Minar, J Chlumsky, Peter Verhamme, P Wells, G Agnelli, A Cohen, Scott Berkowitz, Henri Bounameaux, B Davidson, F Misselwitz, Alexander Gallus, G Raskob, Sebastian Schellong, Annelise Segers

    Research output: Contribution to journalArticle

    1583 Citations (Scopus)

    Abstract

    BACKGROUND: A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism. METHODS: In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. The primary efficacy outcome was symptomatic recurrent venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: Rivaroxaban was noninferior to standard therapy (noninferiority margin, 2.0; P = 0.003) for the primary efficacy outcome, with 50 events in the rivaroxaban group (2.1%) versus 44 events in the standard-therapy group (1.8%) (hazard ratio, 1.12; 95% confidence interval [CI], 0.75 to 1.68). The principal safety outcome occurred in 10.3% of patients in the rivaroxaban group and 11.4% of those in the standardtherapy group (hazard ratio, 0.90; 95% CI, 0.76 to 1.07; P = 0.23). Major bleeding was observed in 26 patients (1.1%) in the rivaroxaban group and 52 patients (2.2%) in the standard-therapy group (hazard ratio, 0.49; 95% CI, 0.31 to 0.79; P = 0.003). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. (Funded by Bayer HealthCare and Janssen Pharmaceuticals; EINSTEIN-PE ClinicalTrials.gov number, NCT00439777.).

    Original languageEnglish
    Pages (from-to)1287-1297
    Number of pages11
    JournalNew England Journal of Medicine
    Volume366
    Issue number14
    DOIs
    Publication statusPublished - 2012

    Fingerprint Dive into the research topics of 'Oral rivaroxaban for the treatment of symptomatic pulmonary embolism'. Together they form a unique fingerprint.

  • Cite this

    Buller, H., Prins, M., Lensing, A., Decousus, H., Jacobson, B., Minar, E., Chlumsky, J., Verhamme, P., Wells, P., Agnelli, G., Cohen, A., Berkowitz, S., Bounameaux, H., Davidson, B., Misselwitz, F., Gallus, A., Raskob, G., Schellong, S., & Segers, A. (2012). Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine, 366(14), 1287-1297. https://doi.org/10.1056/NEJMoa1113572